A Multicenter study on the proper use and safety of ponatinib based on PK/PD/PGx

A Multicenter study on the proper use and safety of ponatinib based on PK/PD/PGx - A Multicenter study on the proper use and safety based on PK/PD/PGx

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035292

Enrollment

Registered

2018-12-17

Start date

2018-12-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myeloid leukemia, Ph1 positive acute lymphoblastic leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patient has been diagnosed with any of the following by chtomosome or genetic test:i)CML-CP,ii)CML-AP,iii)CML-BC,iv)Ph+ALL. 2) Patient who has been registered to post marketing surveillance of ponatinib. 3) Age at registration is of 20 years or older. 4) Written informed consent is taken.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Time to vascular occlusive event	—

Secondary

Measure	Time frame
Complete hematologic response, Complete cytogentic response, Major molecular response, Drug concentration	—

Countries

Japan

Contacts

Public ContactKenichi Miyamoto

National Cancer Center Hospital East Department of Hematology

kenmiyam@east.ncc.go.jp0471331111

Outcome results